Today, the FDA announced approval for SKYCLARYS (omaveloxolone) in treating Friedreich’s Ataxia. This is the first and only FDA-approved prescription medicine for Friedreich’s Ataxia. NAF is thrilled about this announcement and proud to have been involved in the process, from clinical trial recruitment to educating our community about the drug development process and how treatments for Ataxia will be accessed. Thank you to all the FA patients who participated in research to make this possible! Read the full press release from Reata Pharmaceuticals, Inc. for more details: Reata Pharmaceuticals Inc. - Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia
#friedreichsataxia #ataxia #RareDiseaseDay #ataxiaawareness